Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
J Virol
1994 Jan 01;681:25-33. doi: 10.1128/JVI.68.1.25-33.1994.
Show Gene links
Show Anatomy links
Inhibition of human immunodeficiency virus type 1 Tat-dependent activation of translation in Xenopus oocytes by the benzodiazepine Ro24-7429 requires trans-activation response element loop sequences.
Braddock M
,
Cannon P
,
Muckenthaler M
,
Kingsman AJ
,
Kingsman SM
.
???displayArticle.abstract???
Two benzodiazepine compounds, [7-chloro-5-(2-pyrryl)-3H-1,4 benzodiazapin-2-(H)-one] (Ro5-3335) and [7-chloro-5-(1H-pyrrol-2-yl)-3H-benzo[e] [1,4] diazepin-2-yl]- methylamine (Ro24-7429), inhibit human immunodeficiency virus type 1 (HIV-1) replication via a specific effect on the function of the transactivator protein, Tat. To gain further insight into the mechanism of action of these compounds, we have tested their effects in an alternative assay for Tat activation in Xenopus oocytes. In this system, translation of trans-activation response element (TAR)-containing RNA is activated by Tat. Both compounds specifically blocked activation of translation in a dose-dependent fashion, with Ro24-7429 showing the greater potency. In the Xenopus oocyte system, as in mammalian cells, mutation of the TAR loop sequences abolishes Tat action. However, it is possible to obtain TAR-specific, Tat-dependent activation of a target RNA with a mutation in the loop provided that this target is in large excess. This result has been interpreted as indicating that a negative factor has been titrated (M. Braddock, R. Powell, A.D. Blanchard, A.J. Kingsman, and S.M. Kingsman, FASEB J. 7:214-222, 1993). Interestingly Ro24-7429 was unable to inhibit the TAR-specific but loop sequence-independent mode of translational activation. This finding suggests that a specific loop-binding cellular factor may mediate the effects of this inhibitor of Tat action. Consistent with this notion, we could not detect any effect of Ro24-7429 on the efficiency of specific Tat binding to TAR in vitro.
Alonso,
Human chromosome 12 is required for optimal interactions between Tat and TAR of human immunodeficiency virus type 1 in rodent cells.
1992, Pubmed
Alonso,
Human chromosome 12 is required for optimal interactions between Tat and TAR of human immunodeficiency virus type 1 in rodent cells.
1992,
Pubmed
Berkhout,
Tat trans-activates the human immunodeficiency virus through a nascent RNA target.
1989,
Pubmed
Blanchard,
An adenosine at position 27 in the human immunodeficiency virus type 1 trans-activation response element is not critical for transcriptional or translational activation by Tat.
1992,
Pubmed
,
Xenbase
Braddock,
A nuclear translational block imposed by the HIV-1 U3 region is relieved by the Tat-TAR interaction.
1990,
Pubmed
,
Xenbase
Braddock,
HIV-1 TAT "activates" presynthesized RNA in the nucleus.
1989,
Pubmed
,
Xenbase
Braddock,
Blocking of Tat-dependent HIV-1 RNA modification by an inhibitor of RNA polymerase II processivity.
1991,
Pubmed
,
Xenbase
Braddock,
HIV-1 TAR RNA-binding proteins control TAT activation of translation in Xenopus oocytes.
1993,
Pubmed
,
Xenbase
Calnan,
Arginine-mediated RNA recognition: the arginine fork.
1991,
Pubmed
Colvin,
Unusual structure of the human immunodeficiency virus type 1 trans-activation response element.
1992,
Pubmed
Cullen,
Regulation of HIV-1 gene expression.
1991,
Pubmed
Delling,
Conserved nucleotides in the TAR RNA stem of human immunodeficiency virus type 1 are critical for Tat binding and trans activation: model for TAR RNA tertiary structure.
1992,
Pubmed
Desai,
Isolation of a cellular protein that binds to the human immunodeficiency virus Tat protein and can potentiate transactivation of the viral promoter.
1991,
Pubmed
Dimitrov,
Quantitation of human immunodeficiency virus type 1 infection kinetics.
1993,
Pubmed
Dingwall,
Human immunodeficiency virus 1 tat protein binds trans-activation-responsive region (TAR) RNA in vitro.
1989,
Pubmed
Dingwall,
HIV-1 tat protein stimulates transcription by binding to a U-rich bulge in the stem of the TAR RNA structure.
1990,
Pubmed
Feng,
HIV-1 tat trans-activation requires the loop sequence within tar.
1988,
Pubmed
Gatignol,
Characterization of a human TAR RNA-binding protein that activates the HIV-1 LTR.
1991,
Pubmed
Gentz,
Bioassay for trans-activation using purified human immunodeficiency virus tat-encoded protein: trans-activation requires mRNA synthesis.
1989,
Pubmed
Gunnery,
Tat-responsive region RNA of human immunodeficiency virus type 1 stimulates protein synthesis in vivo and in vitro: relationship between structure and function.
1992,
Pubmed
Hart,
TAR loop-dependent human immunodeficiency virus trans activation requires factors encoded on human chromosome 12.
1993,
Pubmed
Hsu,
Inhibition of type 1 human immunodeficiency virus replication by a tat antagonist to which the virus remains sensitive after prolonged exposure in vitro.
1993,
Pubmed
Hsu,
Inhibition of HIV replication in acute and chronic infections in vitro by a Tat antagonist.
1991,
Pubmed
Johnston,
Autoradiography using storage phosphor technology.
1990,
Pubmed
Kim,
Temporal aspects of DNA and RNA synthesis during human immunodeficiency virus infection: evidence for differential gene expression.
1989,
Pubmed
Luo,
Functional analysis of interactions between Tat and the trans-activation response element of human immunodeficiency virus type 1 in cells.
1993,
Pubmed
Madore,
Genetic analysis of the cofactor requirement for human immunodeficiency virus type 1 Tat function.
1993,
Pubmed
Marciniak,
Identification and characterization of a HeLa nuclear protein that specifically binds to the trans-activation-response (TAR) element of human immunodeficiency virus.
1990,
Pubmed
Masuda,
Modulation of host cell nuclear proteins that bind to HIV-1 trans-activation-responsive element RNA by phorbol ester.
1993,
Pubmed
Muesing,
Regulation of mRNA accumulation by a human immunodeficiency virus trans-activator protein.
1987,
Pubmed
Nelbock,
A cDNA for a protein that interacts with the human immunodeficiency virus Tat transactivator.
1990,
Pubmed
Ohana,
The type 1 human immunodeficiency virus Tat binding protein is a transcriptional activator belonging to an additional family of evolutionarily conserved genes.
1993,
Pubmed
Pauwels,
Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives.
1990,
Pubmed
Puglisi,
Conformation of the TAR RNA-arginine complex by NMR spectroscopy.
1992,
Pubmed
Ratnasabapathy,
The HIV-1 long terminal repeat contains an unusual element that induces the synthesis of short RNAs from various mRNA and snRNA promoters.
1990,
Pubmed
Rosen,
The location of cis-acting regulatory sequences in the human T cell lymphotropic virus type III (HTLV-III/LAV) long terminal repeat.
1985,
Pubmed
Rounseville,
Binding of a host cell nuclear protein to the stem region of human immunodeficiency virus type 1 trans-activation-responsive RNA.
1992,
Pubmed
Sanger,
DNA sequencing with chain-terminating inhibitors.
1977,
Pubmed
Sarver,
Frontiers in HIV-1 Therapy: fourth conference of the NIAID National Cooperative Drug Discovery Groups-HIV.
1992,
Pubmed
Selby,
Trans-activation by HIV-1 Tat via a heterologous RNA binding protein.
1990,
Pubmed
Sheline,
Two distinct nuclear transcription factors recognize loop and bulge residues of the HIV-1 TAR RNA hairpin.
1991,
Pubmed
Southgate,
Activation of transcription by HIV-1 Tat protein tethered to nascent RNA through another protein.
1990,
Pubmed
Southgate,
The HIV-1 Tat protein activates transcription from an upstream DNA-binding site: implications for Tat function.
1991,
Pubmed
Sullenger,
Analysis of trans-acting response decoy RNA-mediated inhibition of human immunodeficiency virus type 1 transactivation.
1991,
Pubmed
Sumner-Smith,
Critical chemical features in trans-acting-responsive RNA are required for interaction with human immunodeficiency virus type 1 Tat protein.
1991,
Pubmed
Weeks,
Fragments of the HIV-1 Tat protein specifically bind TAR RNA.
1990,
Pubmed
Witvrouw,
Cell type-specific anti-human immunodeficiency virus type 1 activity of the transactivation inhibitor Ro5-3335.
1992,
Pubmed
Wu,
tat regulates binding of the human immunodeficiency virus trans-activating region RNA loop-binding protein TRP-185.
1991,
Pubmed
